Morgan Stanley analyst Simeon Gutman downgrades Five Below (NASDAQ:FIVE) from Overweight to Equal-Weight and raises the price target from $225 to $230.
Heat Biologics Q2 EPS $(0.26) Up From $(0.35) YoY, Sales $459.49M Up From $593.16K YoY
Heat Biologics (NASDAQ:HTBX) reported quarterly losses of $(0.26) per share. This is a 25.71 percent increase over losses of $(0.35) per share from the same period last year. The company reported $459.49 million in
